Publikationen


Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging

01.04.2023

Abu Sammour, D., Cairns, J.L., Boskamp, T. et al. Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging. Nat Commun 14, 1823 (2023). https://doi.org/10.1038/s41467-023-37394-z Published: 01 April 2023 Abstract Mass spectrometry imaging vows to enable simultaneous spatially resolved investigation of hundreds of metabolites in tissues, but it primarily relies on traditional ion images for

... weiter lesen

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11

11.02.2023

Judmann B, Wängler B, Schirrmacher R, Fricker G, Wängler C* (2023) Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11. Pharmaceuticals, 16(2), 273. DOI: 10.3390/ph16020273. Abstract The human epidermal growth factor receptor (EGFR) is closely related to several cancer-promoting processes and overexpressed on a variety of tumor types, rendering it an important target structure for the imaging

... weiter lesen

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE.

30.01.2023

Eschbach RS, Hofmann M, Späth L, Unterrainer LM, Sheikh GT, Delker A, Lindner S, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Tiling R, Brendel M, Wenter V, Dekorsy FJ, Zacherl MJ, Todica A, Ilhan H, Grawe F, Cyran CC, Unterrainer M, Rübenthaler J, Knoesel T, Paul T, Boeck S, Westphalen CB, Spitzweg C, Auernhammer

... weiter lesen

Synthesis, Radiolabeling, in Vitro and in Vivo Characterization of Heterobivalent Peptidic Agents for bispecific EGFR and Integrin αvβ3 Targeting

04.01.2023

Braun D, Judmann B, Cheng X, Wängler B, Schirrmacher R, Fricker G, Wängler C* (2023) Synthesis, Radiolabeling, in Vitro and in Vivo Characterization of Heterobivalent Peptidic Agents for bispecific EGFR and Integrin αvβ3 Targeting. ACS Omega, 8(2), 2793−2807. DOI: 10.1021/acsomega.2c07484. Abstract Radiolabeled heterobivalent peptidic ligands (HBPLs) are a highly promising compound class for the sensitive

... weiter lesen

Dynamic Contrast-Enhanced MR Imaging Evaluation of Perfusional Changes and Ablation Zone Size after Combination Embolization and Ablation Therapy

19.12.2022

Jason Chiang, MD, PhD, Hiro Sparks, MD, Johann S. Rink, MD, M. Franca Meloni, MD, Frank Hao, MD, Kyung H. Sung, PhD, and Edward W. Lee, MD, PhD Journal of Vascular and Interventional Radiology https://doi.org/10.1016/j.jvir.2022.10.041 Available online 8 November 2022 Received 4 June 2022, Revised 29 September 2022, Accepted 28 October 2022, Available online 8

... weiter lesen

Synthesis of a new bifunctional cross-bridged chelating agent, peptide conjugation, and comparison of 68Ga-labeling and complex stability characteristics with established chelators

19.10.2022

Damerow H, Wängler B, Schirrmacher R, Fricker G, Wängler C* (2023) Synthesis of a new bifunctional cross-bridged chelating agent, peptide conjugation, and comparison of 68Ga-labeling and complex stability characteristics with established chelators. ChemMedChem 18(1), e202200495. DOI: 10.1002/cmdc.202200495. Graphical Abstract The new backbone-modified bifunctional cross-bridged chelating agent CB-DO2A-GA was developed, introduced into the peptide Tyr3-octreotate and

... weiter lesen

Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging – Which Chelator is the Most Suitable?

04.10.2022

Damerow H, Cheng X, von Kiedrowski V, Schirrmacher R, Wängler B, Fricker G, Wängler C* (2022) Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging – Which Chelator is the Most Suitable? Pharmaceutics 14(10), 2114. DOI: 10.3390/pharmaceutics14102114. Published: 4 October 2022 https://doi.org/10.3390/pharmaceutics14102114 Abstract 89Zr represents a highly favorable positron emitter for

... weiter lesen

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET

05.09.2022

Wängler C, Beyer L, Bartenstein P, Wängler B, Schirrmacher R, Lindner S (2022) Favorable SSTR Subtype Selectivity of SiTATE: New momentum for clinical [18F]SiTATE PET. EJNMMI Radiopharmacy and Chemistry, 7(1), 22. DOI: 10.1186/s41181-022-00176-x. Published 05 September 2022 DOI: https://doi.org/10.1186/s41181-022-00176-x

... weiter lesen

Synthetic Arterial Spin Labeling MRI of the Kidneys for Evaluation of Data Processing Pipeline

31.07.2022

I. Brumer, D. Bauer, L. Schad and F. Zöllner. Synthetic Arterial Spin Labeling MRI of the Kidneys for Evaluation of Data Processing Pipeline. Diagnotsics, 2022, 12 (8), p.1854 . Published: 31 July 2022 https://doi.org/10.3390/diagnostics12081854 Abstract Accurate quantification of perfusion is crucial for diagnosis and monitoring of kidney function. Arterial spin labeling (ASL), a completely non-invasive magnetic

... weiter lesen

Towards the development of GE11-based radioligands for imaging of EGFR-positive tumors

28.07.2022

Judmann B, Braun D, Schirrmacher R, Wängler B, Fricker G, Wängler C* (2022) Towards the development of GE11-based radioligands for imaging of EGFR-positive tumors. ACS Omega, 7(31), 27690–27702. DOI: 10.1021/acsomega.2c03407. Publication Date: July 28, 2022 https://doi.org/10.1021/acsomega.2c03407 Abstract The epidermal growth factor receptor (EGFR) is closely associated with tumor development and progression and thus an important

... weiter lesen